BIBLIOGRAFÍA RECOMENDADA
1. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2(8454):515-8.

2. Hull R, Delmore T, Genton E, Hirsch J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. New England Journal of Medicine 1979;301(16):855-8.

3. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine 1982;307(27):1676-81.

4. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. New England Journal of Medicine 1982;306(4):189-94.

5. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs and Aging 1999;14(4):303 - 312.

6. Hettiarachchi RJK, Prins MH, Lensing AWA, Büller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Current Opinion in Pulmonary Medicine 1998;4:220-25.

7. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine 1995;332(20):1330-5.

8. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis & Haemostasis 1994;71(1):7-11.

9. Kelton JG, Warkentin TE. Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination. American Journal of Clinical Pathology 1995;104(6):611-3.


10. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996; 20: 521–527.

11. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999; 81: 26–31.

12. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999; 30: 283–292.

13. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost. 2000; 84: 559–564.

14. Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001; 33: 77–90.

15. Kearon C. Long-Term Management of Patients After Venous Thromboembolism. Circulation. 2004;110:I-10 – I-18.

16. van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Büller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN study group. Thrombosis & Haemostasis 1998;79(2):258-63.

17. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thrombosis & Haemostasis 1999;81:668-72.